Tim Hirst

Cryptopharma Pty Ltd. develops novel anti-inflammatory therapeutic agents for the treatment of pulmonary diseases. It focuses on the development of CP92, a treatment of Cystic Fibrosis. The company was founded by Alastair George Stewart and John Lambert in October 2000 and is headquartered in Victoria, Australia.

Savine Therapeutics Pty Ltd. develops vaccines for infectious diseases. The company was founded by Scott Anthony Thomson and Ian Alistair Ramshaw and is headquartered in Canberra, Australia.

Warm Contact Pty Ltd. designs and manufactures optical devices for contact lens, which improves contact lens case hygiene. Its first product is a lens warmer that offers patient comfort and is particularly useful to new users of contact lens who experience the anxiety surrounding the initial shock of inserting cool lenses into their eyes. The company is headquartered in Canberra, Australia.

ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia.

Dosimetry & Imaging Pty Ltd. develops X-ray storage phosphor for use in radiation detection and medical imaging. The firm specializes in detecting radiation exposure for use in personal dosimetry, homeland security and medical therapeutic products and measures life time exposure and reduces an individual’s exposure. The company was founded by Hans Riesen in 2007 and is headquartered in Sydney, Australia.

Synergetic Services Pty Ltd. develops software solutions. It also provides third generation Internet-based personal loan fulfillment services which enable choice of loan product & financial institution and performs real-time identity, credit validation & approval of loan applications. The company is headquartered in Canberra, Australia.

Gamma Vaccines Pty Ltd. develops broad-spectrum vaccines against influenza and bacterial pneumonia. The firm is also seeking opportunities to exploit its technology platform for veterinary applications, including the production of novel avian influenza vaccines for preventing bird flu outbreaks in poultry. The company was founded by Tim Hirst, Mohammed Alsharif and Jean Petre in July 2009 and is headquartered in Manuka, Australia.

GPN Vaccines Ltd. is an Australian biotechnology company that is developing a vaccine called Gamma-PN™ to protect against all strains of Streptococcus pneumoniae, which causes life-threatening pneumonia, bacteremia, meningitis, and middle ear infections. The company is based in Adelaide, Australia, and Tim Hirst has been the CEO since 2017. This disease is responsible for causing 1-2 million deaths worldwide each year, particularly in children.